Physostigmin: Von der gottesurteilsbohne zum modernen antidot und therapeutikum

Medizinische Monatsschrift fur Pharmazeuten

Volumn 19, Issue 9, 1996, Pages 252-260

  Walter, Kersten ^a   Aschoff, Jürgen C ^b  

^a ASTELLAS PHARMA INC   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDOTE; ATROPINE; ORGANOPHOSPHORUS COMPOUND; PHYSOSTIGMINE; TUBOCURARINE CHLORIDE;

ALZHEIMER DISEASE; ATAXIA; DRUG EFFICACY; DRUG INDICATION; DRUG INFORMATION; DRUG MECHANISM; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; ORAL DRUG ADMINISTRATION; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION;

ANTIDOTES; CHOLINESTERASE INHIBITORS; HUMANS; PHYSOSTIGMINE;

EID: 0029817774     PISSN: 03429601     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Arendt T. Neurobiologische Grundlagen der Alzheimerschen Erkrankung. Klinikarzt 1995:24.386-95.
2. Aschoff JC. Kailer N, Walter K Physostigmin in der Behandlung von Klemhirnataxien. Nervenarzt 1996:67:311-8.
3. Aschoff JC. Physostigmine forcerebellar ataxias: the fantasies of a clinical neurologist and the problems in developing a legalized therapeutic system (TTS). Eur J Pharm Sci 1994;2:28.
4. Aschoff JC, Kailer N. Physostigmine in treatment of cerebellar ataxia In Chopra JC. Sawhney IMS, editors. Progress in Neurology. New Delhi: Churchill Livingstone. 1995: 294-305.
5. Balfour JH. Description of the plant which produces the ordeal bean of Calabar. Trans R Soc Edinburgh 1861:22:305-12.
6. Becker RE, Giacobini E. Pharmacokinetics and pharmacodynamics of acetylcholinesterase inhibition: Can acetylcholine levels in the brain be improved in Alzheimer's disease? Drug Dev Res 1988:14:235-46.
7. Blitt CD, Petty WC. Reversal of lorazepam delirium by physostigmine. Anesth Analg 1975;54:607-8.
8. Christison R. On the properties of the ordeal bean of old Calabar Western Africa. Mon J Med Sci (London, Edinburgh) 1855;20: 193-204
9. Crowell EB, Ketchum JS. The treatment of scopolamine-induced delirium with physostigmine. Clin Pharmacol Ther 1967,8.409-14.
10. Cumming G, Harding LK, Prowse K. Treatment and recovery after massive overdose of physostigmine. Lancet 1968;2.147-9.
11. DeFeudis F. V Central cholinergic systems, cholinergic drugs and Alzheimer's disease - an overview Drugs Today 1988;24:473-90.
12. Duvoisin RC, Katz R. Reversal of central anticholinergic syndrome in man by physostigmine. J Am Med Assoc 1968:206.1963-5.
13. Fraser TR. On the characters, actions, and the-rapeutical uses of the ordeal bean of Calabar. Edinburgh Med J 1863;9:36-56. 123-32. 235-48
14. Forth W, Henschler D. Rummel W. Allgemeine und spezielle Pharmakologie, 5. Auflage. Mannheim. Bibliographisches Institut & F A. Brockhaus AG, 1987.
15. Gennings C. Carchman RA. Carter WH. Campell ED. et al. Assessing physostigmine efficacy by response surface modeling A comparison to pyridostigmine efficacy. J Am Col Toxicol 1988;7:1013-30.
16. Giacobini E. Pharmacotherapy of Alzheuner disease: New drugs and novel strategies. In: Cuello AC. Progress in Brain Research 98. Elsevier Science Publishers. 1993:447-54.
17. Gilman AG, Rail TW, Nies AS, Taylor P, editors. Goodman and Oilman's. The Pharmacological Basis of Therapeutics, eighth edition. Mc Graw-Hill, Inc. Health Professions Division. 1992.
18. Granacher RP. The central anticholinergic syndrome: Management with physostigmine. J Ky Med Assoc 1975,75:147-50.
19. Granacher RP, Baldessarini RJ. Physostigmine. Its use in acute anticholinergic syndrome with antidepressant and antiparkinson drugs. Arch Gen Psychiatry 1975;32:375-80.
20. Greig NH, Pei XF, Soncrant TT, Ingram DK, et al. Phenserine and ring C hetero-analogues: Drug candidates for the treatment of Alzheimer's disease. Med Res Rev 1995; 15:3-31.
21. Jenike MA, Albert MS, Baer L, Oral physostigmine as treatment for dementia of the Alzheimer type: A long-term outpatient trial. Alzheimer Dis Assoc Disord 1990;4:226-31.
22. Jobst J. Hesse O. Uber die Bohne von Calabar. Ann Chem Pharm 1864;129:115-21
23. Kanazawa I, Kwak S, Sasaki H, Mizusasawa H, et al. Studies on neurotransmitter markers and neuronal cell density in the cerebellar system in olivopontocerebellar atrophy and cortical cerebellar atrophy. J Neurol Sci 1985;71:193-208.
24. Kark RAP, Blass JP, Spence MA. Physostigmine in familial ataxias. Neurology 1977;27.70-2.
25. Kark RAP, Budelli MMR, Wachsner R Double-blind, triple-crossover trial of low doses of oral physostigmine in inherited ataxias. Neurology 1981;31:288-92.
26. Kish SJ, Schul L, Simmons J, Gilbert J. et al. Brain acetylcholinesterase activity is markedly reduced in dominants-inherited olivopontocerebellar atrophy. J Neurol Neurosurg Psychiatry 1988;51:544-8.
27. Knobloch O, Schlosser M, Diednch U, Kreuz F. Direkte DNA-Diagnostik einer Form der spinozerebellären Ataxien jetzt möglich. Dtsch Arztebl 1995;92:A1102-4.
28. Kumar V, Calache M. Treatment of Alzheirner's disease with cholmergic drugs, Int J Clin Pharmacol Ther Toxicol 1991;29:23-37.
29. Kurz A. Diagnose und Differentialdiagnose der (Alzheimer-)Demenz. Dtsch Apoth 1995;47:591-4.
30. Levy A, Brandeis R. Treves TA, Meshulam Y, et al Transdermal physostigmine in the treatment of Alzheimer's disease. Alzheimer Dis Assoc Disord 1994;8:15-21.
31. Paulus W, Bancher C, Jellinger K. Die Neuropathologie der Demenzen. Dtsch Arztebl 1995;92:B2340-5.
32. Rothberger JC. Uber die gegenseitigen Bezie-hungen zwischen Curare und Physostigmin. Arch Ges Physiol 1901;87:117-69.
33. RumackBH. Anticholinergic poisoning: Treatment with physostigmine. Pediatrics 1973; 52:449-51.
34. Schneck HJ, Tempel G, v. Hundelshausen B. Zur Beeinflussung der postanaesthetischen Vigilanzminderung durch Physostigmin und Naloxon. In: Tempel G. Physostigmin und post-narkotische Vigilanz. Stuttgart: Gustav Fischer Verlag. 1989:37-42.
35. Somani SM, Dube SN. Physostigmine - an overview as pretreatment drug for orsanophosphate intoxication. Int J Clin Pharmacol Ther Toxicol 1989;27:367-87.
36. Somani SM, Khalique A. Distribution and pharmacokinetics of physostigmine in rat after intramuscular administration. Fundam Appl Toxicol 1986;6:327-34.
37. Stojek A. Bilikiewicz A, Wolny S. Local physostigmine in the management of early alcohol withdrawal. Br J Addict 1987;82:927-30.
38. Tam YK. Individual variation in first-pass metabolism. Clin Pharmacokin 1993;25:300-28.
39. Thomsen T, Kaden B, Fischer JP, Bickel U. et al. Inhibition of acetylcholinesterase activity in human brain tissue and erythrocytes by galanthamine. physostigmine and tacrine. Eur J Clin Chem Clin Biochem 1991;29:487-92.
40. Tijssen CC, Endtz LJ, Goor C. The influence of physostigmine on visual-vestibular interaction in hereditary ataxias. J Neurol Neurosurg Psychiatry 1995;48:977-81.
41. Vee A, Leven M. De l'alcaloide de la feve de Calabar et experiences physiologiques avec ce même alcaloide. J Pharm Chimie 1865,1:70-2.
42. Vogel HL. Intravenous use of physostigmine in the management of acute diazepam intoxication J Am Osteopath Assoc 1977;76:349-51
43. Walker MB. Treatment of myasthenia gravis with physostigmine. Lancet 1934;226:1200-1.
44. Waiter K, Muller M, Barkworth MF, Nieciecki AV, et al. Pharmacokinetics of physostigmine in man following a single application of a transdermal system. Br J Clin Pharmacol 1995; 39:59-63.
45. Wu YQ, Remecke E, Lin ET, Theoharides AD, et al. High performance liquid Chromatographic method for detection of physostigmine and eseroline in plasma using a silica gel column and a perchloric acid mobile phase. J Chromatogr 1990;13:275-90.